Significant Value of 11C-Acetate and 18F-Fluorodeoxyglucose PET/Computed Tomography on 90Y Microsphere Radioembolization for Hepatocellular Carcinoma

Ho, Chi Lai; Chen, Sirong; Cheung, Shing Kee; Leung, TW

doi:10.1016/j.cpet.2019.06.005

Cited by 6 publications

(13 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CT-CAP (a) showed a solitary rounded 7 mmsize lung nodule (arrows). The WB-PET/MRI confirmed an infracentimetric lung nodule visible on morphologic sequences (T1-weighted after gadolinium injection) (b) with hyperintensity on b800 s/mm² DWI (c) and 18 F-FDG hypermetabolism (d) leading to the diagnosis of lung metastasis. The followup CT scan (e,f) performed three months after the WB-PET/MRI showed a significant progression of the number and size of lung nodules, confirming the metastatic status.…”

Section: Figurementioning

confidence: 82%

“…Moreover, on CT-CAP, a retroperitoneal nonspecific lymph node was observed (e), visible on morphologic MRI sequence (f). Both diffusion restriction (g) and 18 F-FDG hypermetabolism (h) were observed Figure 3. A 65-year-old BCLC C patient referred for a WB-PET/MRI before liver transplantation.…”

Section: Figurementioning

confidence: 99%

“…On CT-CAP, no bone lesion was visible (a). The WB-PET/MRI revealed an infracentimetric bone lesion with enhancement after Gadolinium-chelate injection (b), together with hyperintensity on DWI (c), and focal hypermetabolism on 18 F-FDG-PET (d) leading to the diagnosis of bone metastasis. Moreover, on CT-CAP, a retroperitoneal nonspecific lymph node was observed (e), visible on morphologic MRI sequence (f).…”

Section: Figurementioning

confidence: 99%

“…Similarly, 18F FluoroDesoxyGlucose ( 18 F-FDG PET/CT) optimizes HCC staging and therapeutic management [12,13]. It upgrades metastatic staging, especially for lymph node involvement and bone metastases [14,15], improves treatment allocation for patients on the waiting list for liver transplantation [16], and enables a response assessment after TARE [17,18]. Whole-body 18 F-FDG PET/MRI (WB-PET/MRI) is an emerging hybrid modality, which appears highly promising in oncology settings [19][20][21].…”

Section: Introductionmentioning

confidence: 99%

“…It upgrades metastatic staging, especially for lymph node involvement and bone metastases [14,15], improves treatment allocation for patients on the waiting list for liver transplantation [16], and enables a response assessment after TARE [17,18]. Whole-body 18 F-FDG PET/MRI (WB-PET/MRI) is an emerging hybrid modality, which appears highly promising in oncology settings [19][20][21]. PET/MRI theoretically provides both optimal local staging by liver MRI, metastatic staging with WB-MRI potentially equivalent to or better than that of standard technologies, and 18F FDG-PET prognostic information in a one-stop-shop imaging approach.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Impact of the 18F-FDG-PET/MRI on Metastatic Staging in Patients with Hepatocellular Carcinoma: Initial Results from 104 Patients

Vermersch

Mulé

Chalaye

et al. 2021

JCM

View full text Add to dashboard Cite

Optimal HCC therapeutic management relies on accurate tumor staging. Our aim was to assess the impact of 18F-FDG-WB-PET/MRI on HCC metastatic staging, compared with the standard of care CT-CAP/liver MRI combination, in patients with HCC referred on a curative intent or before transarterial radioembolization. One hundred and four consecutive patients followed for HCC were retrospectively included. The WB-PET/MRI was compared with the standard of care CT-CAP/liver MRI combination for HCC metastatic staging, with pathology, followup, and multidisciplinary board assessment as a reference standard. Thirty metastases were identified within 14 metastatic sites in 11 patients. The sensitivity of WB-PET/MRI for metastatic sites and metastatic patients was significantly higher than that of the CT-CAP/liver MRI combination (respectively 100% vs. 43%, p = 0.002; and 100% vs. 45%, p = 0.01). Metastatic sites missed by CT-CAP were bone (n = 5) and distant lymph node (n = 3) in BCLC C patients. For the remaining 93 nonmetastatic patients, three BCLC A patients identified as potentially metastatic on the CT-CAP/liver MRI combination were correctly ruled out with the WB-PET/MRI without significant increase in specificity (100% vs. 97%; p = 0.25). The WB-PET/MRI may improve HCC metastatic staging and could be performed as a “one-stop-shop” examination for HCC staging with a significant impact on therapeutic management in about 10% of patients especially in locally advanced HCC.

show abstract

Section: Figurementioning

confidence: 82%

Section: Figurementioning

confidence: 99%

Section: Figurementioning

confidence: 99%